Core Insights - Autolus Therapeutics plc is participating in the Jefferies Global Healthcare Conference in London, with CEO Dr. Christian Itin scheduled to present on November 18, 2025 [1]. Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases [3]. - The company utilizes proprietary and modular T cell programming technologies to create targeted and controlled T cell therapies aimed at effectively recognizing and eliminating target cells [3]. - Autolus has a marketed therapy named AUCATZYL and is developing a pipeline of product candidates for hematological malignancies, solid tumors, and autoimmune diseases [3]. Event Details - A webcast of the fireside chat will be available on the company's website, with a replay archived for 90 days post-presentation [2].

Core Insights - Autolus Therapeutics plc is set to release its third quarter 2025 financial results and operational highlights on November 12, 2025, before the U.S. market opens [1] - A conference call and webcast will be held at 8:30am EST / 1:30pm GMT to discuss the financial results and provide a business update [2] - Autolus specializes in next-generation programmed T cell therapies for cancer and autoimmune diseases, utilizing proprietary T cell programming technologies [3] Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering T cell therapies [3] - The company has a marketed therapy, AUCATZYL, and a pipeline targeting hematological malignancies, solid tumors, and autoimmune diseases [3] - The company aims to engineer T cell therapies that can better recognize and eliminate target cells by overcoming their defense mechanisms [3]

Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary and modular T cell programming technologies to create targeted and controlled T cell therapies [3] - Autolus has a marketed therapy named AUCATZYL and a pipeline of candidates for treating hematological malignancies, solid tumors, and autoimmune diseases [3] Stock Option Awards - The compensation committee of Autolus granted stock option awards to purchase a total of 360,550 shares to 60 employees under the 2025 Inducement Plan [1] - The exercise price for the options is set at $2.47 per share, matching the closing price of Autolus' common stock on July 9, 2025 [2] - Each option has a ten-year term and vests over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 equal monthly installments, contingent on continued service [2]

Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary and modular T cell programming technologies to create targeted and highly active T cell therapies [3] - Autolus has an FDA-approved product, AUCATZYL, and a pipeline of candidates for treating hematological malignancies, solid tumors, and autoimmune diseases [3] Upcoming Events - Autolus will participate in the 24th Annual Needham Virtual Healthcare Conference [1] - CEO Dr. Christian Itin is scheduled to present in a Fireside Chat on April 9, 2025, at 9:30 AM EDT / 14:30 PM BST [1] - A webcast of the presentation will be available on the company's website and archived for 90 days [2]